JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2017, Vol. 31 ›› Issue (2): 49-54.doi: 10.6040/j.issn.1673-3770.0.2017.017

Previous Articles     Next Articles

Construction of c-Met target chimeric antigen receptor T cells and evaluation the role on nasopharyngeal carcinoma cells.

  

  1. 1. Deparment of Otolaryngology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu, China;2. Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing 210029, Jiangsu, China;3. Medical Research Institute of Nanjing Military Region, Nanjing 210002, Jiangsu, China
  • Received:2017-01-11 Online:2017-04-16 Published:2017-04-16

Abstract: Objective To construct c-Met target chimeric antigen receptors(chimeric antigen receptor, CAR)retrovirus vector and to explore its expression and effects of modified T lymphocytes on the c-Met positive nasopharyngeal carcinoma cells. Methods Genetic engineering method was used to construct the c-Met scFv, and then the c-Met scFv was inserted into retrovirus vector containing signaling molecules such as CD28, CD137 and CD3ζ.The build c-Met CAR retrovirus vector was confirmed by sequencing. Western blotting was used to analyze c-Met CAR expression in T lymphocyte after the virus vector infected T lymphocyte. CCK8 assay was employed to detect the cytotoxicity against the nasopharyngeal carcinoma cell lines, and changes of IFN-γ and IL-2 was analyzed by ELISA after c-Met CAR-T co-culture with nasopharyngeal carcinoma cells. Results The sequencing result showed that the c-Met CAR vector sequences were right. Western blotting could detect the expression of CD3ζ. CCK-8 assay indicated that c-Met CAR-T cells suppressed proliferation of nasopharyngeal carcinoma cells, and ELISA assay demonstrated that c-Met CAR-T cells could effectively release IFN-γ and IL-2 with the help of nasopharyngeal carcinoma cells. Conclusion c-Met CAR retrovirus vector was established successfully. The CAR could be expressed by the vector in T cells. c-Met CAR-T inhibited proliferation of c-Met positive nasopharyngeal carcinoma cells and increased the secretion of IFN-γ and IL-2.

Key words: Nasopharyngeal carcinoma, c-Met, Chimeric antigen receptor

CLC Number: 

  • R739.62
[1] 刘孟忠. 鼻咽癌治疗新进展[J]. 广东医学, 2014, 35(1):1-4.
[2] 张煜, 封青, 胡军. 肿瘤的细胞免疫治疗研究进展[J]. 生物技术通讯, 2012, 23(3):440-443. ZHANG Yu, FENG Qing, HU Jun. Research progress on cellular immunotherapy for tumor[J]. Lett Biotechnol, 2012, 23(3):440-443.
[3] Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design[J]. Cancer Discov, 2013, 3(4):388-398.
[4] Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors[J]. Cancer Discov, 2016, 6(2):133-146.
[5] Luan T, Yu Y. Increased hepatocyte growth factor and c-Met receptor expression in nasopharyngeal carcinoma[J]. Int J Clin Exp Med, 2014, 7(12):5583-5587.
[6] Toiyama Y, Yasuda H, Saigusa S, et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer[J]. Int J Cancer, 2012, 130(12):2912-2921.
[7] 刘崇梅, 于惠芝, 林明晖, 等. HGF/c-Met系统在鼻咽癌中的表达及其与增殖细胞核抗原的关系[J]. 现代肿瘤医学,2009,17(11):2087-2090. LIU Chongmei, YU Huizhi, LIN Minghui, et al. Expression of HGF/c-Met system and its relationship with expression of PCNA in nasopharyngeal carcinoma[J]. J Mod Oncol, 2009, 17(11):2087-2090.
[8] 白璐月,刘金荣,唐奇,等. 人源全分子抗c-Met抗体的制备及对鼻咽癌细胞生物学特性的影响[J]. 南京医科大学学报(自然科学版), 2016, 36(6):687-692. BAI Luyue, LIU Jinrong, TANG Qi, et al. Preparation of full molecule human anti-c-Met antibody and its effects on nasopharyngeal carcinoma cells[J]. Acta Univ Med Nanjing(Natural Sci), 2016, 36(6):687-692.
[9] Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor[J]. Blood, 2010, 116(7):1035-1044.
[10] Whilding LM, Maher J. ErbB-targeted CAR T-cell immunotherapy of cancer[J]. Immunotherapy, 2015, 7(3):229-241.
[11] Turtle CJ, Riddell SR, Maloney DG. CD19-targeted chimeric antigen receptor-modified T cell immunotherapy for B cell malignancies[J]. Clin Pharmacol Ther, 2016, 100(3):252-258.
[12] Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases[J]. Clin Cancer Res, 2015, 21(14):3149-3159.
[13] Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity[J]. Mol Ther, 2013, 21(4):904-912.
[14] Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J]. Blood, 2011, 118(23):6050-6056.
[1] LIN Xiaoxue, LIN Baorui, LI Peishan, LU Biaoqing. Application of electronic nasopharyngoscopy combined with narrow band imaging in traditional Chinese medicine syndrome differentiation of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(3): 40-46.
[2] WANG Sheng, LI Yindan, YANG Jinji. The role of microRNA in nasopharyngeal carcinoma and its research progress [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 125-131.
[3] QIU Qianhui, XIAO Xuping, YANG Qintai, YE Jing, DENG Zeyi, WANG Desheng, TAN Guolin, JIANG weihong,. Expert consensus on clinical management recommendations for carotid blowout syndrome secondary to NPC treatment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 1-18.
[4] WANG Siquan, ZHU Hongshen, ZHANG Xiaobin, ZHAO Zhouyang, MA Yue, YANG Yimei, HUANG Lijin. Analysis of factors associated with stroke and cranial nerve palsy after unilateral internal carotid artery embolization in patients with nasopharyngeal carcinoma after radiotherapy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 19-25.
[5] HUANG Qiao, REN Yi, HOU Tao, LIAO Xingwei, ZHU Zi’ang, ZHAN Xiaolin, LIU Ying, YIN Shihua. Expression of EphB2 in nasopharyngeal carcinoma tissues and its correlation with clinicopathological characteristics [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 26-30.
[6] SUN Chunxiao, WANG Wenqing, YUE Tian, LIU Jisheng. Efficacy analysis of concurrent chemoradiotherapy with high and low cumulative cisplatin doses in the treatment of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 31-41.
[7] WANG Zaixing, TANG Zhiyuan, LI Dingbo, SHI Zhaohui, ZENG Xianhai, ZHANG Qiuhang. Treatment of internal carotid artery rupture caused by tumor recurrence and skull base osteonecrosis after radiotherapy for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 49-58.
[8] SUN Fang, XIE Chubo, QIU Qianhui. Retrospective analysis of nutritional indexes and their impact on wound healing in patients with radiation-induced skull base osteoradionecrosis after treatment with nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 59-68.
[9] ZHU Ruikai, WU Jiarong, SUN Fang, XIE Chubo, QIU Qianhui. Computed tomography angiography-based assessment of internal carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma and its associated factors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 77-84.
[10] QIN Debo, XUE Jiancheng, YANG Wenyue, HU Bing, CHEN Tao, YU Yanping, MENG Qingguo, SUN Huanji, MIAO Beiping, LU Yongtian. Changing the diagnosis and treatment of nasopharyngeal cancer: biomarkers and nasal endoscopic surgery synergise to advance early treatment development [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 85-92.
[11] WU Jiarong, QIU Qianhui. The role and significance of the skull base fascial tissue barrier in endoscopic resection of locally early recurrent nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 108-113.
[12] YANG Ming, LIU Xuexia, ZHANG Hua. Progress of m6A recognition protein IGF2BPs in head and neck cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 153-161.
[13] WU Min, LI Zhengyang, MENG Jie, YE Huiping. Molecular mechanisms of programmed cell death and its role in nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 152-157.
[14] ZHANG Maohua, WEI Rifu, ZHU Zhongshou, LIU Ping, GAO Shang, LI Huifeng. Effect of LncRNA PCAT-1 on the biological behaviour and chemosensitivity of nasopharyngeal carcinoma cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 68-76.
[15] ZHANG Jingyi, DONG Xiangyi, MU Yakui, SONG Xicheng. Research progress on pyroptosis in otorhinolaryngology diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 140-148.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!